[ Price : $8.95]
A group of academic and public health experts urges FDA to embrace greater transparency, scientific independence and regulatory co...[ Price : $8.95]
FDA converts the accelerated approval of Eli Lilly's Retevmo (selpercatinib) into a traditional approval for treating adult and pe...[ Price : $8.95]
FDA warns South El Monte, CA-based International Medication Systems about CGMP violations in its production of finished drugs.[ Price : $8.95]
FDA warns Pleasant Hill, CA-based ZIIP Inc. about Quality System violations in its production of adulterated and misbranded unappr...[ Price : $8.95]
Biogen executives attempt to reassure investors Tuesday that its experimental anti-tau Alzheimer's disease therapy remains a promi...[ Price : $8.95]
DTC Perspectives CEO Bob Ehrlich warns that an upcoming FDA proposal to eliminate the adequate provision standard could amount to ...[ Price : $8.95]
Ascelia Pharma pushes back against FDA's recent public release of a Complete Response Letter for its MRI contrast agent Orviglance...[ Price : $8.95]
GSK says its PD-1 inhibitor Jemperli (dostarlimab) achieved the primary endpoint in a registrational Phase 2 trial in patients wit...